3 research outputs found
Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations–State-of-the-Art.
No full textCancer and COVID-19 are both well-established risk factors predisposing to thrombosis. Both disease entities are correlated with increased incidence of venous thrombotic events through multifaceted pathogenic mechanisms involving the interaction of cancer cells or SARS-CoV2 on the one hand and the coagulation system and endothelial cells on the other hand. Thromboprophylaxis is recommended for hospitalized patients with active cancer and high-risk outpatients with cancer receiving anticancer treatment. Universal thromboprophylaxis with a high prophylactic dose of low molecular weight heparins (LMWH) or therapeutic dose in select patients, is currentlyindicated for hospitalized patients with COVID-19. Also, prophylactic anticoagulation is recommended for outpatients with COVID-19 at high risk for thrombosis or disease worsening. However, whether there is an additive risk of thrombosis when a patient with cancer is infected with SARS-CoV2 remains unclear In the current review, we summarize and critically discuss the literature regarding the epidemiology of thrombotic events in patients with cancer and concomitant COVID-19, the thrombotic risk assessment, and the recommendations on thromboprophylaxis for this subgroup of patients. Current data do not support an additive thrombotic risk for patients with cancer and COVID-19. Of note, patients with cancer have less access to intensive care unit care, a setting associated with high thrombotic risk. Based on current evidence, patients with cancer and COVID-19 should be assessed with well-established risk assessment models for medically ill patients and receive thromboprophylaxis, preferentially with LMWH, according to existing recommendations. Prospective trials on well-characterized populations do not exist
A Florentine family in crisis: the Strozzi in the fifteenth century.
No full textPhDIn 1434 the Strozzi lineage had held a leading position in
Florentine society and government for at least one hundred and fifty
years, and was one of the largest and wealthiest of the city's
patrician lineages. The records of the catasto of 1427 and of the
scrutiny of 1433 are used to give a profile of the dominant social,
economic and political position of the Strozzi before the advent of
Medicean dominance. Their record of electoral success, and the
political and cultural leadership of influential and respected men
such as Palla di Nofri and Matteo di Simone, with other factors, put
the Strozzi amongst the greatest enemies of the victorious Medicean
regime of late 1434. The effects of political opposition and exile
on the lineage are examined both directly, through records of office-holding,
and indirectly through such indicators as marriage alliances
and household wealth. The two most prominent lines of the Strozzi
were exiled after 1434. Palla di Nofri's life and preoccupations in
his Paduan exile are examined, together with the lives of his sons;
none of these Strozzi ever returned to Florence, pursued as they were
by the enmity of the Medicean regime. The very different careers of
Filippo di Matteo and his brother Lorenzo are also examined: how they
succeeded in founding a lucrative bank in Naples, and in returning to
Florence to 'rebuild' (rifare) the position of the Strozzi lineage
there. The final decades of the century saw the Strozzi in an
economically more secure position, due substantially to the efforts
of Filippo. Except for a very small number of its members admitted
into the regime, most of the lineage is here shown to have remained
excluded from significant political office until after the fall of
the Medici regime in 1494
Thromboembolic Disease in Patients With Cancer and COVID-19:Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations–State-of-the-Art
No full textCancer and COVID-19 are both well-established risk factors predisposing to thrombosis. Both disease entities are correlated with increased incidence of venous thrombotic events through multifaceted pathogenic mechanisms involving the interaction of cancer cells or SARS-CoV2 on the one hand and the coagulation system and endothelial cells on the other hand. Thromboprophylaxis is recommended for hospitalized patients with active cancer and high-risk outpatients with cancer receiving anticancer treatment. Universal thromboprophylaxis with a high prophylactic dose of low molecular weight heparins (LMWH) or therapeutic dose in select patients, is currently indicated for hospitalized patients with COVID-19. Also, prophylactic anticoagulation is recommended for outpatients with COVID-19 at high risk for thrombosis or disease worsening. However, whether there is an additive risk of thrombosis when a patient with cancer is infected with SARSCoV2 remains unclear. In the current review, we summarize and critically discuss the literature regarding the epidemiology of thrombotic events in patients with cancer and concomitant COVID-19, the thrombotic risk assessment, and the recommendations on thromboprophylaxis for this subgroup of patients. Current data do not support an additive thrombotic risk for patients with cancer and COVID-19. Of note, patients with cancer have less access to intensive care unit care, a setting associated with high thrombotic risk. Based on current evidence, patients with cancer and COVID-19 should be assessed with well-established risk assessment models for medically ill patients and receive thromboprophylaxis, preferentially with LMWH, according to existing recommendations. Prospective trials on well-characterized populations do not exist
